Active, not recruiting Head and Neck Neoplasms trials: Trial Insights

Filters: Condition: Head and Neck Neoplasms Status: Active, not recruiting Clear all

138 trials match Source: ClinicalTrials.gov registrations

Trials started per year
Category	Trials
2005	1
2006	1
2010	3
2011	3
2014	1
2015	4
2016	7
2017	9
2018	10
2019	15
2020	7
2021	21
2022	14
2023	20
2024	11
2025	9
2026	2

Trials by status
Category	Trials
Active, not recruiting	138

Top lead sponsors
Category	Trials
M.D. Anderson Cancer Center	13
Memorial Sloan Kettering Cancer Center	5
Providence Health & Services	4
Dana-Farber Cancer Institute	3
University of California, San Francisco	3
ALX Oncology Inc.	2
Abramson Cancer Center at Penn Medicine	2
Ain Shams University	2
AstraZeneca	2
Eli Lilly and Company	2

Top conditions
Category	Trials
Head and Neck Neoplasms	138
Squamous Cell Carcinoma of Head and Neck	40
Carcinoma, Non-Small-Cell Lung	18
Neoplasms	15
Oropharyngeal Neoplasms	15
Ovarian Neoplasms	14
Lung Neoplasms	13
Melanoma	13
Breast Neoplasms	11
Endometrial Neoplasms	11

Trials

Showing 26 to 50 of 138. Each trial links to its page on Pharma Observatory.

A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202 NCT06062420Phase 2Active, not recruitingGlaxoSmithKlineStarted 2023
Testing the Safety of Giving a Standard Dose of Radiation Over a Shorter Period of Time for Patients Who Had Surgery for Intermediate-Risk Head and Neck Cancer NCT05540899Phase 1Active, not recruitingAmerican College of RadiologyStarted 2023
Nutrition Throughout the Treatment Course - Expanding Care From Hospital to Home NCT05997329Not applicableActive, not recruitingUniversity of OsloStarted 2023
Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma NCT05980000Phase 2Active, not recruitingWashington University School of MedicineStarted 2023
Assessing Impact of Early Physiotherapy on Lymphatic Dysfunction in Head and Neck Cancer Survivorship NCT05937269Phase 1Active, not recruitingThe University of Texas Health Science Center, HoustonStarted 2023
Stereotactic Radiotherapy for Sinonasal Malignancy NCT06617910ObservationalActive, not recruitingTaichung Veterans General HospitalStarted 2023
A Prospective Imaging Study of the Integrated TrueBeam-HyperSight CBCT System NCT05975619Not applicableActive, not recruitingVarian, a Siemens Healthineers CompanyStarted 2023
Study Transplanting Bone Marrow Cells Into Salivary Glands to Treat Dry Mouth Caused by Radiation Therapy NCT05820711Phase 1Active, not recruitingUniversity of Wisconsin, MadisonStarted 2023
Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform (ELEPHAS-02) NCT05520099ObservationalActive, not recruitingElephasStarted 2023
A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors NCT05812027ObservationalActive, not recruitingTScan Therapeutics, Inc.Started 2023
ENHANCE - Evaluating the Implementation of Head and Neck Cancer E-health NCT05785247ObservationalActive, not recruitingGuy's and St Thomas' NHS Foundation TrustStarted 2023
ChatBot and Activity Monitoring in Patients Undergoing Chemoradiotherapy NCT05318027Phase 2Active, not recruitingAbramson Cancer Center at Penn MedicineStarted 2023
Evaluating a Low-Cost Therapeutic Device in Managing Head and Neck Cancer Patients With Radiation-Related Trismus NCT05671861Not applicableActive, not recruitingUniversity of California, San FranciscoStarted 2023
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors NCT05787587Phase 1Active, not recruitingIDEAYA BiosciencesStarted 2023
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors NCT05704985Phase 1Active, not recruitingDEKA BiosciencesStarted 2023
3D Specimen Maps for RT Planning NCT05743569ObservationalActive, not recruitingVanderbilt University Medical CenterStarted 2023
Predictive Tools in Head and Neck Cancer Patients Undergoing Radiotherapy NCT06806683ObservationalActive, not recruitingFondazione Policlinico Universitario Agostino Gemelli IRCCSStarted 2023
First in Human Study of AZD9592 in Solid Tumors NCT05647122Phase 1Active, not recruitingAstraZenecaStarted 2022
A Clinical Study to Investigate the Efficacy of Tigilanol Tiglate Directly in Head and Neck Cancer NCT05608876Phase 2Active, not recruitingQBiotics Group LimitedStarted 2022
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers NCT05544929Phase 1Active, not recruitingNovartis PharmaceuticalsStarted 2022
Non-randomized, Open-label Study of Intralesional Nivolumab for High Risk Oral Premalignant Lesions NCT05327270Phase 1Active, not recruitingM.D. Anderson Cancer CenterStarted 2022
TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers NCT05108870Phase 1/2Active, not recruitingUniversity of ChicagoStarted 2022
Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies NCT05226871Phase 2Active, not recruitingPfizerStarted 2022
Docetaxel/Pembrolizumab in Head and Neck Squamous Cell Carcinoma NCT05252429Phase 2Active, not recruitingHokkaido University HospitalStarted 2022
Safety and Efficacy of APG-157 in Head and Neck Cancer NCT05312710Phase 2Active, not recruitingAveta Biomics, Inc.Started 2022

38 more trials match. See them on Pharma Observatory

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.

Visit Pharma Observatory